What is the 13F Pro Quality Score for WVE?

13F Pro ranks Wave Life Sciences, Inc. (WVE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View WVE's current score at https://13fpro.ai/company/WVE (free sign-up required for the full ranking).

Which hedge funds own the most WVE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of WVE include RA CAPITAL MANAGEMENT, L.P., BlackRock,, GSK plc. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/WVE as soon as new 13F filings post.

Where does 13F Pro source WVE data?

All Wave Life Sciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Wave Life Sciences, Inc. files with the SEC under CIK 1631574. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is WVE in?

Wave Life Sciences, Inc. (WVE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is WVE research updated on 13F Pro?

WVE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Wave Life Sciences, Inc.(WVE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1631574 WVE stock profile & AI dashboard →

13F Pro Quality Score

7.5/100

Rank #2,941 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

4.5/100

Profitability

4.0/100

Balance Sheet

3.6/100

Earnings Quality

11.6/100

Free Cash Flow

3.4/100

Institutional Flow

41.0/100

Revenue Scale

10.3/100

Dilution Risk

4.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why WVE Scores 8/100

exact factor attribution · 2026-09-11

WVE's composite is held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

-0.5 pts

41th pct

Shareholder dilution

-2.3 pts

4th pct

Earnings growth

-2.3 pts

4th pct

Earnings quality

-3.8 pts

12th pct

Capital efficiency

-4.6 pts

4th pct

Scale

-6.0 pts

10th pct

Profitability

-6.9 pts

4th pct

Free cash flow

-7.0 pts

3th pct

Revenue growth

-9.1 pts

5th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

WVE Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Wave Life Sciences, Inc. (WVE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores WVE at 7.5/100 on a 32-signal composite quality model, placing it at rank #2,941 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (3.4) and balance sheet strength (3.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Wave Life Sciences, Inc. reports quarterly revenue of $2.3M, net income of $-69.4M, free cash flow of $-54.5M. Top institutional holders of WVE by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., BlackRock, GSK plc, based on the most recent SEC filings. WVE trades on the Nasdaq exchange and files with the SEC under CIK 1631574. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WVE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Wave Life Sciences, Inc. directly from SEC EDGAR. Wave Life Sciences, Inc.'s 13F Pro composite quality score has ranged between 7 and 27 since 2021, currently 7.5 — a declining long-term trajectory across 60 quarterly and live scoring snapshots.

✦

Fun facts about Wave Life Sciences Ltd.

Quirks, history, and lore behind WVE — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Cambridge, Massachusetts · focused on genetic medicines.
2
The Numbers
Like most clinical-stage biotechs, it runs on partnership revenue and cash reserves rather than product sales — operating losses in the tens of millions per year are the norm here.
3
The History
Founded around 2012, the company was built on a proprietary platform designed to make synthetic nucleic acid therapies more precise and more durable than earlier RNA approaches.
4
The Secret
Its core technology uses stereopure chemistry — controlling the exact three-dimensional shape of each molecule in a way that most rivals cannot, aiming to unlock RNA-targeting drugs with fewer side effects.
5
The Lore
The company has pursued treatments for devastating rare neurological and neuromuscular diseases, including programs targeting Huntington's disease and Duchenne muscular dystrophy.
6
The Giveaway
Its ticker is a ripple in the gene-therapy ocean: a stereopure RNA medicines pioneer whose three-letter symbol could double as something you do with your hand — and whose name evokes the ocean's rhythm.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$2.3M

Net Income

Q2 2026

$-69.4M

Free Cash Flow

Q2 2026

$-54.5M

ROIC

Q2 2026

-65.1%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-60.5% YoY

$42.7MFY 2025

FY22 $3.6MFY23 $113.3MFY24 $108.3MFY25 $42.7M

Net Income

-110.7% YoY

$-204.4MFY 2025

FY22 $-161.8MFY23 $-57.5MFY24 $-97.0MFY25 $-204.4M

Operating Income

-95.1% YoY

$-215.4MFY 2025

FY22 $-162.7MFY23 $-68.0MFY24 $-110.4MFY25 $-215.4M

EPS (Diluted)

-72.9% YoY

$-1.21FY 2025

FY22 $-2.05FY23 $-0.54FY24 $-0.70FY25 $-1.21

Total Assets

+81.3% YoY

$638.5MFY 2025

FY22 $146.4MFY23 $274.9MFY24 $352.2MFY25 $638.5M

Op. Cash Flow

-24.1% YoY

$-187.5MFY 2025

FY22 $-127.8MFY23 $-19.4MFY24 $-151.0MFY25 $-187.5M

Free Cash Flow

-23.9% YoY

$-188.2MFY 2025

FY22 $-129.1MFY23 $-20.5MFY24 $-152.0MFY25 $-188.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$42.7M -60.5%	$108.3M -4.4%	$113.3M +3005.1%	$3.6M -91.1%	$41.0M +104.0%	$20.1M
Net Income	$-204.4M -110.7%	$-97.0M -68.7%	$-57.5M +64.5%	$-161.8M -32.4%	$-122.2M +18.5%	$-149.9M
Operating Income	$-215.4M -95.1%	$-110.4M -62.4%	$-68.0M +58.2%	$-162.7M -28.1%	$-127.0M +17.2%	$-153.4M
EPS (Diluted)	$-1.21 -72.9%	$-0.70 -29.6%	$-0.54 +73.7%	$-2.05 +13.1%	$-2.36	—
Total Assets	$638.5M +81.3%	$352.2M +28.1%	$274.9M +87.8%	$146.4M -29.3%	$207.0M -25.9%	$279.2M
Operating Cash Flow	$-187.5M -24.1%	$-151.0M -677.2%	$-19.4M +84.8%	$-127.8M -43.6%	$-89.0M +23.3%	$-116.0M
Free Cash Flow	$-188.2M -23.9%	$-152.0M -639.6%	$-20.5M +84.1%	$-129.1M -44.2%	$-89.6M +23.7%	$-117.3M

Get alerted when WVE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Wave Life Sciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of WVE

RA CAPITAL MANAGEMENT, L.P.
$156.7M26,975,505 sh
BlackRock, Inc.
$111.6M19,202,461 sh
GSK plc
$106.0M18,245,691 sh
MAVERICK CAPITAL LTD
$59.7M10,278,115 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$31.6M5,443,143 sh
PRIMECAP MANAGEMENT CO/CA/
$31.1M5,354,622 sh
683 Capital Management, LLC
$28.8M4,950,000 sh
FMR LLC
$28.6M4,922,477 sh
STATE STREET CORP
$28.1M4,839,317 sh
READYSTATE ASSET MANAGEMENT LP
$27.5M4,727,139 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$156.7M	26,975,505
BlackRock, Inc.	$111.6M	19,202,461
GSK plc	$106.0M	18,245,691
MAVERICK CAPITAL LTD	$59.7M	10,278,115
DRIEHAUS CAPITAL MANAGEMENT LLC	$31.6M	5,443,143
PRIMECAP MANAGEMENT CO/CA/	$31.1M	5,354,622
683 Capital Management, LLC	$28.8M	4,950,000
FMR LLC	$28.6M	4,922,477
STATE STREET CORP	$28.1M	4,839,317
READYSTATE ASSET MANAGEMENT LP	$27.5M	4,727,139

Companies Similar to WVE

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

IDYA

IDEAYA Biosciences, Inc.

AI score

Very similar · 17 shared holders

GSK plc RTW INVESTMENTS, LP abrdn plc

VYGR

Voyager Therapeutics, Inc.

AI score

Very similar · 8 shared holders

SPHERA FUNDS MANAGEMENT LTD.Susquehanna Portfolio Strategies, LLC Privium Fund Management B.V.

NRIX

Nurix Therapeutics, Inc.

AI score

Very similar · 13 shared holders

BAKER BROS. ADVISORS LP Susquehanna Portfolio Strategies, LLC KENNEDY CAPITAL MANAGEMENT LLC

XNCR

Xencor Inc

AI score

Very similar · 11 shared holders

RA CAPITAL MANAGEMENT, L.P.PRIMECAP MANAGEMENT CO/CA/RTW INVESTMENTS, LP

RCUS

Arcus Biosciences, Inc.

AI score

Very similar · 12 shared holders

abrdn plc BAKER BROS. ADVISORS LP Susquehanna Portfolio Strategies, LLC

EVMN

Evommune, Inc.

AI score

Very similar · 8 shared holders

RA CAPITAL MANAGEMENT, L.P.RTW INVESTMENTS, LP SymBiosis Capital Partners, LLC

TSHA

Taysha Gene Therapies, Inc.

AI score

Very similar · 12 shared holders

RA CAPITAL MANAGEMENT, L.P.RTW INVESTMENTS, LP abrdn plc

NAMS

NewAmsterdam Pharma Co N.V.

AI score

Very similar · 15 shared holders

RA CAPITAL MANAGEMENT, L.P.MAVERICK CAPITAL LTD abrdn plc

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put WVE on your watchlist

Track score changes the day Wave Life Sciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is WVE a good stock to buy?

13F Pro's AI-powered analysis of Wave Life Sciences, Inc. (WVE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for WVE are available on the WVE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. WVE is classified as a small company.

Which hedge funds own WVE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling WVE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Wave Life Sciences, Inc.'s investment landscape.